Diabetes Mellitus, Type 2
Conditions
Brief summary
Assess the safety and tolerability of once daily oral doses of BI 187004 in patients with type 2 diabetes mellitus without oral antidiabetic treatment and in patients on a stable metformin background treatment over 28 days. Assess the effect on fasting plasma glucose after 28 days of treatment and to investigate the pharmacokinetics and pharmacodynamics of BI 187004.
Interventions
DRUGPlacebo
BI 187004 high dose matching placebo once daily
DRUGBI 187004
BI 187004 high dose once daily add on to background metformin
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or postmenopausal or hysterectomised female patients with diagnosis of Type 2 Diabetes Mellitus (T2DM) before informed consent 2. To be eligible for Arm 1 1. Oral antidiabetic mono-therapy for the last 12 weeks prior to Informed Consent AND Glycosylated haemoglobin (HbA1c) \>= 6.5% and \<= 8.5% at Visit 1a 2. Therapy-naïve patients or no antidiabetic treatment within 4 weeks prior to Informed Consent AND HbA1c \>= 7.0% and \<= 9.5% at Visit 1a. 3. To be eligible for Arm 2: a. Antidiabetic treatment with metformin with an unchanged daily dose for 12 weeks prior to Informed Consent AND patient´s willingness to keep this therapy stable during the course of the trial AND HbA1c \>= 7.0% and \<= 9.5% at Visit 1a 4. Age \>=18 and \<=80 years for female hysterectomised and male patients at Visit 1a 5. Age \>=55 and \<=80 years for female postmenopausal (defined by the absence of menses for at least 2 years) patients at Visit 1a 6. Body mass index (BMI) \>= 28 and \<= 40 kg/m2 at Visit 1a 7. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion criteria
1. Treatment with a non-oral antidiabetic therapy or with more than one oral antidiabetic medication within 12 weeks prior to visit 1a. 2. Fasted plasma glucose \> 240 mg/dl (\>13.3 mmol/l) on two consecutive days after screening (Visit 1a) confirmed by a fasted laboratory blood glucose test until first administration of the trial drug 3. Any laboratory value more than 3 times above upper limit normal (ULN) at screening (visit 1a) or any other laboratory value outside the reference range and clinically relevant in the investigator judgment 4. Any known clinically relevant concomitant diseases or chronic diseases other than type 2 diabetes, hyperlipidaemia or medically treated hypertension 5. Medical history of cancer or treatment for cancer in the last five years prior to the Visit 1a. 6. History of Cushing syndrome, Addison´s disease, congenital adrenal hyperplasia or polycystic ovary syndrome 7. Treatment with systemic, inhalatory or ophthalmologic steroids within 12 weeks prior to first administration of the trial drug. 8. Treatment compliance during the run-in period is outside the per protocol range defined range, between 80%-120% treatment compliance. 9. Use of any other concomitant medication within 5 half-lives before the first administration of the trial drug except for allowed co-medication. 10. Surgery or trauma with significant blood loss (more than 500 ml) within the last 3 months prior to informed consent or blood donation (more than 100 ml) within four weeks prior to first administration of study medication or planned during the trial 11. Any other medical condition that would interfere with trial participation based on investigator´s judgement or any on-going clinical condition that would jeopardize patient´s or site personnel´s safety or study compliance based on investigator judgement. Smoking habits interfering with hospitalization. Patients not willing to abstain from alcoholic beverages during inpatient visits 12. Male patients not willing to use adequate contraception (sexual abstinence, condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until three months after the last intake
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of patients with drug- related adverse events | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment | 4 weeks |
Countries
Germany
Outcome results
None listed